findmyKOL
Clinical trialNCT06070012RecruitingPhase 2Interventional

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

SponsorDiwakar DavarEnrollment44Uveal Melanoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Colorado Cancer Center

    Aurora, Colorado, United States

    Sapna Patel, MD
    Recruiting
  • Georgetown University Medical Center

    Washington D.C., District of Columbia, United States

    Suthee Rapisuwon, MD
    Recruiting
  • Upmc Hillman Cancer Center

    Pittsburgh, Pennsylvania, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Aug 2025
Primary completion
30 Sept 2028
Completion
30 Sept 2030
Last update posted
27 Feb 2026
Registered enrollment
44
Registry id
NCT06070012

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.